Roivant Sciences Ltd (ROIV) - Total Liabilities
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has total liabilities worth $251.14 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Roivant Sciences Ltd to assess how effectively this company generates cash.
Roivant Sciences Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Roivant Sciences Ltd (ROIV) asset resilience to evaluate the company's liquid asset resilience ratio.
Roivant Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Roivant Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank of Nanjing Co Ltd
SHG:601009
|
China | CN¥2.77 Trillion |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
USA | $55.40 Billion |
|
Telefónica S.A
F:TNE2
|
Germany | €71.22 Billion |
|
Valterra Platinum Limited
JSE:VAL
|
South Africa | ZAC71.73 Billion |
|
Huatai Securities Co Ltd
SHG:601688
|
China | CN¥853.68 Billion |
|
Baoshan Iron & Steel Co Ltd
SHG:600019
|
China | CN¥152.95 Billion |
|
Jiangsu Zhongtian Technology Co Ltd
SHG:600522
|
China | CN¥25.55 Billion |
|
Principal Financial Group Inc
NASDAQ:PFG
|
USA | $328.99 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Roivant Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ROIV company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roivant Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roivant Sciences Ltd (2019–2025)
The table below shows the annual total liabilities of Roivant Sciences Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $249.74 Million | -67.73% |
| 2024-03-31 | $773.95 Million | -1.03% |
| 2023-03-31 | $782.02 Million | +49.33% |
| 2022-03-31 | $523.70 Million | -0.76% |
| 2021-03-31 | $527.69 Million | +43.25% |
| 2020-03-31 | $368.36 Million | -18.24% |
| 2019-03-31 | $450.51 Million | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more